Middle East Pharmaceutical Industries Past Earnings Performance
Past criteria checks 5/6
Middle East Pharmaceutical Industries's earnings have been declining at an average annual rate of -1.9%, while the Pharmaceuticals industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 23.2% per year. Middle East Pharmaceutical Industries's return on equity is 24%, and it has net margins of 21.1%.
Key information
-1.9%
Earnings growth rate
-1.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 23.2% |
| Return on equity | 24.0% |
| Net Margin | 21.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Middle East Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 359 | 76 | 133 | 0 |
| 31 Dec 23 | 338 | 66 | 129 | 0 |
| 30 Sep 23 | 328 | 63 | 126 | 0 |
| 30 Jun 23 | 318 | 59 | 122 | 0 |
| 31 Mar 23 | 291 | 50 | 117 | 0 |
| 31 Dec 22 | 303 | 59 | 114 | 0 |
| 31 Dec 21 | 287 | 66 | 98 | 0 |
| 31 Dec 20 | 302 | 73 | 95 | 0 |
Quality Earnings: 4016 has high quality earnings.
Growing Profit Margin: 4016's current net profit margins (21.1%) are higher than last year (17.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4016's earnings have declined by 1.9% per year over the past 5 years.
Accelerating Growth: 4016's earnings growth over the past year (51%) exceeds its 5-year average (-1.9% per year).
Earnings vs Industry: 4016 earnings growth over the past year (51%) exceeded the Pharmaceuticals industry 6.8%.
Return on Equity
High ROE: 4016's Return on Equity (24%) is considered high.